Oruka Therapeutics, Inc. (ORKA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$80.15-1.23%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Oruka Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.638
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-2.404
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-2.828

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advancement of ORKA-001 in clinical trials	Oruka Therapeutics is advancing its lead product, ORKA-001, in clinical trials.	Intact	Phase 2 trials fail to meet endpoints	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain cash and equivalents above $1 billion	This financial strength is crucial for reaching regulatory milestones.	Intact	Cash falls below $900 million	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 quarters including 2026-Q2. Cash and equivalents rose from about $496 million in 2026-Q1 to $1.1 billion in 2026-Q2, reflecting capital raises. Management expects this capital to fund operations through the anticipated BLA filing for ORKA-001. The trajectory is delivering with strong cash position supporting development plans. Delivery assessment Oct 24, 2026
Monitor insider trading activity	A supporting condition in Oruka Therapeutics, Inc.'s published investment case. The stated target is No significant insider selling.	Under Pressure	Significant insider selling occurs	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.83

$-2.51 → $-2.83 · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.51	Unavailable	7 / 0
2026-07-25	$-2.51	Unavailable	7 / 0
2026-07-26	$-2.51	Unavailable	7 / 0
2026-07-27	$-2.49	$0	9 / 9
2026-07-28	$-2.51	Unavailable	7 / 0
2026-07-29	$-2.49	$0	9 / 9
2026-07-30	$-2.49	$0	9 / 9
2026-07-31	$-2.49	$0	9 / 9
2026-08-01	$-2.51	Unavailable	7 / 0
2026-08-02	$-2.49	$0	9 / 9
2026-08-03	$-2.49	$0	9 / 9
2026-08-04	$-2.51	Unavailable	7 / 0
2026-08-05	$-2.51	Unavailable	7 / 0
2026-08-06	$-2.51	Unavailable	7 / 0
2026-08-07	$-2.51	Unavailable	7 / 0
2026-08-08	$-2.51	Unavailable	7 / 0
2026-08-09	$-2.49	$0	9 / 9
2026-08-10	$-2.51	Unavailable	7 / 0
2026-08-12	$-2.51	Unavailable	7 / 0
2026-08-13	$-2.51	Unavailable	7 / 0
2026-08-14	$-2.51	Unavailable	7 / 0
2026-08-15	$-2.51	Unavailable	7 / 0
2026-08-16	$-2.51	Unavailable	7 / 0
2026-08-17	$-2.51	Unavailable	7 / 0
2026-08-18	$-2.51	Unavailable	7 / 0
2026-08-19	$-2.51	Unavailable	7 / 0
2026-08-20	$-2.70	Unavailable	7 / 0
2026-08-21	$-2.70	Unavailable	7 / 0
2026-08-22	$-2.70	Unavailable	7 / 0
2026-08-23	$-2.68	Unavailable	7 / 0
2026-08-24	$-2.68	Unavailable	7 / 0
2026-08-25	$-2.73	Unavailable	7 / 0
2026-08-26	$-2.73	Unavailable	7 / 0
2026-08-27	$-2.73	Unavailable	7 / 0
2026-08-28	$-2.73	Unavailable	7 / 0
2026-08-29	$-2.79	Unavailable	7 / 0
2026-08-30	$-2.79	Unavailable	7 / 0
2026-08-31	$-2.79	Unavailable	7 / 0
2026-09-01	$-2.79	Unavailable	7 / 0
2026-09-02	$-2.79	Unavailable	7 / 0
2026-09-03	$-2.79	Unavailable	7 / 0
2026-09-04	$-2.79	Unavailable	7 / 0
2026-09-05	$-2.81	Unavailable	7 / 0
2026-09-06	$-2.81	Unavailable	7 / 0
2026-09-07	$-2.81	Unavailable	7 / 0
2026-09-08	$-2.81	Unavailable	7 / 0
2026-09-09	$-2.81	Unavailable	7 / 0
2026-09-10	$-2.81	Unavailable	7 / 0
2026-09-11	$-2.81	Unavailable	7 / 0
2026-09-12	$-2.81	Unavailable	7 / 0
2026-09-13	$-2.81	Unavailable	7 / 0
2026-09-14	$-2.81	Unavailable	7 / 0
2026-09-15	$-2.81	Unavailable	7 / 0
2026-09-16	$-2.81	Unavailable	7 / 0
2026-09-17	$-2.81	Unavailable	7 / 0
2026-09-18	$-2.81	Unavailable	7 / 0
2026-09-19	$-2.81	Unavailable	7 / 0
2026-09-20	$-2.81	Unavailable	7 / 0
2026-09-21	$-2.81	Unavailable	7 / 0
2026-09-22	$-2.81	Unavailable	7 / 0
2026-09-23	$-2.81	Unavailable	7 / 0
2026-09-24	$-2.81	Unavailable	7 / 0
2026-09-25	$-2.83	Unavailable	7 / 0
2026-09-26	$-2.83	Unavailable	7 / 0
2026-09-27	$-2.83	Unavailable	7 / 0
2026-09-28	$-2.83	Unavailable	7 / 0
2026-09-29	$-2.83	Unavailable	7 / 0
2026-09-30	$-2.83	Unavailable	7 / 0
2026-10-01	$-2.83	Unavailable	7 / 0
2026-10-02	$-2.83	Unavailable	7 / 0
2026-10-03	$-2.83	Unavailable	7 / 0
2026-10-04	$-2.83	Unavailable	7 / 0
2026-10-05	$-2.83	Unavailable	7 / 0
2026-10-06	$-2.83	Unavailable	7 / 0
2026-10-07	$-2.83	Unavailable	7 / 0
2026-10-08	$-2.83	Unavailable	7 / 0
2026-10-09	$-2.83	Unavailable	7 / 0
2026-10-10	$-2.83	Unavailable	7 / 0
2026-10-11	$-2.83	Unavailable	7 / 0
2026-10-12	$-2.83	Unavailable	7 / 0
2026-10-13	$-2.83	Unavailable	7 / 0
2026-10-14	$-2.83	Unavailable	7 / 0
2026-10-15	$-2.83	Unavailable	7 / 0
2026-10-16	$-2.83	Unavailable	7 / 0
2026-10-17	$-2.83	Unavailable	7 / 0
2026-10-18	$-2.83	Unavailable	7 / 0
2026-10-19	$-2.83	Unavailable	7 / 0
2026-10-20	$-2.83	Unavailable	7 / 0
2026-10-21	$-2.83	Unavailable	7 / 0
2026-10-22	$-2.83	Unavailable	7 / 0
2026-10-23	$-2.83	Unavailable	7 / 0
2026-10-24	$-2.83	Unavailable	7 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	13	0	0
2026-06-01	13	0	0
2026-07-01	13	0	0
2026-08-01	13	0	0
2026-09-01	13	0	0
2026-10-01	13	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Advancement of ORKA-001 in clinical trialsDirect metric needs a verified mapping
Maintain cash and equivalents above $1 billionDirect metric needs a verified mapping
Monitor insider trading activityPublished status: Under Pressure

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-36.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Oruka Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a clinical-development growth story, not an established earnings compounder: the business is loss-making and recent financial performance is weak. The thesis is on watch, with management advancing key trials and reporting enough cash to fund development through the anticipated ORKA-001 BLA filing, a regulatory application for approval.

What's priced into Oruka Therapeutics, Inc.

The evidence does not provide a valuation measure or clear market expectations, so whether ORKA is cheap, fair, or expensive versus peers cannot be assessed. No pricing fragility signals fired, but that does not establish that clinical or financial risks are already reflected in expectations.

What the fundamentals likely do

Near term, financial performance may remain uneven: ORKA reported an earnings miss in August, and the snapshot flags a 42% miss probability because the industry has a high miss rate and peers have missed lately. Over the multi-year view, management reports progress on ORKA-001 and ORKA-002 trials, while the $1.1 billion cash position supports planned development; the recent increase in sector context is a tailwind, not proof of company-level improvement.

What Oruka Therapeutics, Inc. hinges on

The longer-term case hinges on ORKA-001 advancing from Phase 2b toward planned Phase 3 initiation in the first half of 2027, and on ORKA-002 trial progress and expected early-2027 data. Near term, a weakening jobs trend could weigh on cyclical names, while sector bellwethers’ results and guidance could either sustain or weaken the Healthcare tailwind.